CNBC September 24, 2024
Key Points
– Novo Nordisk’s top executive faces a Senate grilling over the high prices of the company’s weight loss drug Wegovy and diabetes treatment Ozempic.
– The Danish drugmaker’s CEO, Lars Fruergaard Jørgensen, is testifying at the Senate Health, Education, Labor and Pensions Committee hearing on Tuesday in Washington, D.C.
– Sen. Bernie Sanders, who chairs the Senate panel, argues that Novo Nordisk charges Americans substantially higher prices for its blockbuster injections than it does for patients in other countries.
Novo Nordisk‘s top executive faced a Senate grilling on Tuesday over the high prices of the company’s weight loss drug Wegovy and diabetes treatment Ozempic, as demand for both injections soars in the U.S.
Novo Nordisk CEO Lars...
Today's Sponsors
Today's Sponsor